Warfarin Dosing
  > Warfarin Dosing
 
  > Clinical Trial
 
> Outcomes
> Hemorrhage Risk
 
> Patient Education
 
> Contact Us
 
> References
> Glossary
> About Us
     
    User:
Patient:
Version 4.0
Build : May 2, 2024
     
   
    Clinical Trial Home > 30 Days Outcome
 30 Day Outcomes 
   
 
Thank you for using www.WarfarinDosing.org. To help us improve this non-profit site, we ask that you provide an INR value and warfarin dose after ~30 days of therapy:
Patient Code:  
Email:
The INR value after ~30 days of warfarin was:
Note: If the patient stopped warfarin before becoming therapeutic,
please enter "1" for INR and "0" for daily dose.
The daily warfarin dose after ~30 days of therapy was:  mg/day.
Note: if the patient alternates doses, please enter the average warfarin dose.
Did the patient have a new thrombotic or ischemic event within 30 days after beginning warfarin or at a screening ultrasound?              
If yes, please indicate type of event(s):
DVT detected without screening  
DVT detected on routine screening  
Ischemic stroke  
Myocardial infarction  
Pulmonary embolism (PE)  
Transient ischemic attack  
Other 
Did the patient have a bleed within 30 days after beginning warfarin?
        
If yes, please indicate type of bleed(s):
Major bleed 
Minor bleed 
Occult bleed  
Other comments or adverse events:
Thank you for helping us to improve this site.

 

 
 

 


©Washington University in St. Louis.

  Caution - Investigational Device. Limited by Federal(or United States) law to investigational use.

Terms of Use : This web site is not intended to substitute for care by a licensed healthcare professional. This Web site is provided on an “as is” basis only and without warranty or representation (whether express or implied) as to its accuracy or reliability. Neither Dr. Brian F. Gage, Washington University, Kimo Migo LLC and Nous Cloud LLC, the NHLBI, or any sponsor are responsible for or accepts liability for any direct or indirect loss or damages arising from or connected to the use of this information.

Commercial use of this Web site and any part thereof, including the dosing algorithm contained herein, is prohibited without written authorization. Supported by the NIH (R01 HL HL097036 and HL074724) and the American Heart Association. If you would like to make a donation to support this non-profit site, click here.

Web site created by Kimo Migo LLC and Nous Cloud LLC.